echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Watson Bio's 2022 Q1 financial report: revenue increased by 51%

    Watson Bio's 2022 Q1 financial report: revenue increased by 51%

    • Last Update: 2022-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 28, Watson Bio released its financial report for the first quarter of 2022.


    During the reporting period, the Yuxi Watson 13-valent pneumonia conjugate vaccine, a subsidiary of Watson, received batches of 2,085,700 doses, an increase of 26.


    During the reporting period, the details of Watson's products in the registration and application stage are as follows:

    In terms of international business, Yuxi Watson's 13-valent pneumonia conjugate vaccine has obtained the market license in Morocco and completed the registration in Morocco


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.